scispace - formally typeset
C

Cora Dejelo

Researcher at Case Western Reserve University

Publications -  4
Citations -  858

Cora Dejelo is an academic researcher from Case Western Reserve University. The author has contributed to research in topics: Transplantation & Cellular immunity. The author has an hindex of 4, co-authored 4 publications receiving 839 citations. Previous affiliations of Cora Dejelo include University Hospitals of Cleveland & Harvard University.

Papers
More filters
Journal Article

Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes.

TL;DR: Improved ability to define the strength of the allospecific immune response by enzyme-linked immunospot assay may allow improved pairing of recipients with donors and identification of kidney allograft donor-recipient pairs at high risk for acute rejection, thus permitting targeted interventions aimed at prolonging graft survival.
Journal ArticleDOI

Enzyme Linked Immunosorbent Spot (ELISPOT) Assay for Interferon‐Gamma Independently Predicts Renal Function in Kidney Transplant Recipients

TL;DR: Increased levels of early alloreactivity measured with this ELISPOT assay may serve as a surrogate for chronic allograft dysfunction and show an independent correlation between early cellular allore activity and long‐term renal function.
Journal ArticleDOI

Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool.

TL;DR: An enzyme‐linked immunosorbent spot (ELISPOT) assay for detection of peripheral blood alloimmunity is developed and provides the foundation for improving the care of human transplant recipients through rational clinical decision‐making based on measures of immune function.
Journal ArticleDOI

Alloreactivity in Renal Transplant Recipients with and without Chronic Allograft Nephropathy

TL;DR: Overall, the results suggest that persistent cell-mediated and humoral alloimmunity contribute to the development of CAN and further demonstrate that anti-donor immunity in patients with CAN is heterogeneous.